NASDAQ:KPTIKaryopharm Therapeutics Stock Price, Forecast & News

Karyopharm Therapeutics' stock was trading at $21.24 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, KPTI shares have decreased by 2.8% and is now trading at $20.65. View which stocks have been most impacted by Coronavirus.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Karyopharm Therapeutics.

Karyopharm Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Karyopharm Therapeutics.

Karyopharm Therapeutics Inc (NASDAQ:KPTI) released its quarterly earnings data on Tuesday, May, 5th. The company reported ($0.78) EPS for the quarter, missing the consensus estimate of ($0.69) by $0.09. The business earned $18.14 million during the quarter, compared to the consensus estimate of $21.59 million. Karyopharm Therapeutics had a negative return on equity of 208.07% and a negative net margin of 316.53%. View Karyopharm Therapeutics' earnings history.

9 analysts have issued 12 month target prices for Karyopharm Therapeutics' shares. Their forecasts range from $25.00 to $40.00. On average, they anticipate Karyopharm Therapeutics' share price to reach $30.63 in the next twelve months. This suggests a possible upside of 48.3% from the stock's current price. View analysts' price targets for Karyopharm Therapeutics.

Media stories about KPTI stock have trended somewhat positive on Monday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Karyopharm Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutKaryopharm Therapeutics.

Some companies that are related to Karyopharm Therapeutics include Reata Pharmaceuticals (RETA), United Therapeutics (UTHR), Myokardia (MYOK), Forty Seven (FTSV), Emergent Biosolutions (EBS), Mirati Therapeutics (MRTX), Ultragenyx Pharmaceutical (RARE), PPD (SDGR), BridgeBio Pharma (BBIO), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), GW Pharmaceuticals PLC- (GWPH), Evotec (EVTCY), Allakos (ALLK) and ChemoCentryx (CCXI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Crispr Therapeutics (CRSP), Bristol-Myers Squibb (BMY), Micron Technology (MU), Alibaba Group (BABA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Amarin (AMRN).

Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI."

Karyopharm Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (7.29%), Janus Henderson Group PLC (4.45%), State Street Corp (4.44%), Frontier Capital Management Co. LLC (2.52%), Wellington Management Group LLP (1.91%) and Emerald Advisers LLC (1.43%). Company insiders that own Karyopharm Therapeutics stock include Christopher Brett Primiano, Jatin Shah, Ltd Chione, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel and Sharon Shacham. View institutional ownership trends for Karyopharm Therapeutics.

KPTI stock was sold by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Two Sigma Investments LP, Nuveen Asset Management LLC, Invesco Ltd., Rafferty Asset Management LLC, Mutual of America Capital Management LLC, Morgan Stanley, and Aigen Investment Management LP. Company insiders that have sold Karyopharm Therapeutics company stock in the last year include Christopher Brett Primiano, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Ran Frenkel, and Sharon Shacham. View insider buying and selling activity for Karyopharm Therapeutics.

KPTI stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Frontier Capital Management Co. LLC, Rice Hall James & Associates LLC, BlackRock Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Sphera Funds Management LTD., and Two Sigma Advisers LP. View insider buying and selling activity for Karyopharm Therapeutics.

Shares of KPTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of KPTI stock can currently be purchased for approximately $20.65.

Karyopharm Therapeutics has a market capitalization of $1.51 billion and generates $40.89 million in revenue each year. The company earns $-199,590,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Karyopharm Therapeutics employs 332 workers across the globe.

The official website for Karyopharm Therapeutics is www.karyopharm.com.

Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The company can be reached via phone at 617-658-0600 or via email at [email protected]